Pair page
Ipamorelin with MK-677
Mechanism-tag overlap and published literature for Ipamorelin and MK-677, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
growth-hormone-secretagogueselective-ghrelin-receptor-agonist
oral-ghrelin-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Ipamorelin and MK-677 have published these mechanism-level observations. Not a co-administration recommendation.
Not a concurrent stack — these are substitutes. Both are GHS-R1a agonists. MK-677 is oral, long-acting, and elevates cortisol/prolactin/appetite more; ipamorelin is injected, short-acting, and cleaner. Users choose based on convenience vs selectivity trade-off.
Quick facts
Ipamorelin
MK-677
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2014 | Ipamorelin | Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. PMID: 2… PMID 25331030 | human trial |
| — | Ipamorelin | ClinicalTrials.gov. Study of IPAMORELIN on the Management of Postoperative Ileus Following Partial Bowel Resection. NCT00672074. | human trial |
| 2008 | Ipamorelin | Veldhuis JD, Keenan DM. Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men. Eur J Endocrinol. 2008;159(5):547-554. PMID: 18728125. PMID 18728125 | human study |
| 2008 | Ipamorelin | Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485. (MK-677 comparator data.) PMID 18981485 | human study |
| 2001 | Ipamorelin | Ghigo E, Arvat E, Giordano R, et al. Biologic activities of growth hormone secretagogues in humans. Endocrine. 2001;14(1):87-93. PMID: 11322506. PMID 11322506 | human study |
| 1999 | Ipamorelin | Gobburu JVS, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. PMID: 10496658. PMID 10496658 | human study |
| 2012 | Ipamorelin | Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-155. PMID: 27186126. PMID 27186126 | preclinical, in vivo |
| 2000 | Ipamorelin | Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569-577. PMID: 10828840. PMID 10828840 | preclinical, in vivo |
| 2020 | Ipamorelin | Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37. doi: 10.1002/rco2.9. | mechanism / discovery |
| 1998 | Ipamorelin | Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822. (The foundational discovery paper; establishes the selectivity claim.) PMID 9849822 | mechanism / discovery |
| 2026 | Ipamorelin | World Anti-Doping Agency. The 2026 Prohibited List. Section S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. | regulatory / registry |
| 2025 | Ipamorelin | U.S. Food and Drug Administration. Bulk Drug Substances That Raise Significant Safety Risks (Category 2) Under Section 503A / 503B. FDA.gov. Updated 2025. | regulatory / registry |
| 2011 | MK-677 | Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183… PMID 20855119 | human trial |
| 2005 | MK-677 | Khojasteh-Bakht SC, Jones HM, Hirota T, Chen J, Lin DC, Harms AC, Vicini P, Cutler DL, Lalovic B. Pharmacokinetics of ibutamoren mesylate (MK-677) in healthy subjects. Br J Clin Pharmacol. 2005;59(5):595-602. | human study |
| 2004 | MK-677 | Bach MA, Rockwood K, Zetterberg C, Thamsborg G, Hébert R, Devogelaer JP, Christiansen JS, Aspray TJ, Boonen S, Dalsky G, Dietz F, Dressler DE, Lang T, Papanicolaou DA. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2… | human study |
| 1999 | MK-677 | Murphy MG, Bach MA, Plotkin D, Bolognese J, Thompson J, Lichtlen P, Sullivan P, Walton H, Ying S, Daifotis AG. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res.… | human study |
| 1998 | MK-677 | Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditur… PMID 9661080 | human study |
| 1996 | MK-677 | Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogo… PMID 8954023 | human study |
| 2025 | MK-677 | WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. | regulatory / registry |
| 2025 | MK-677 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2). Pharmacy Compounding Advisory Committee. Updated 2025. | regulatory / registry |
| 2020 | MK-677 | Shiimura Y, Horita S, Hamamoto A, Asada H, Hirata K, Tanaka M, Mori K, Uemura T, Kobayashi T, Iwata S, Kojima M. Structure of an antagonist-bound ghrelin receptor reveals possible ghrelin recognition mode. Nat Commun. 2020;11(1):4160. PMID: 32814772. PMID 32814772 | research article |
| 2018 | MK-677 | Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28870384. PMID 28870384 | research article |
| 2001 | MK-677 | Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Cli… PMID 11238495 | research article |
| 1997 | MK-677 | Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt MJ Jr, Fisher MH, Nargund RP, Patchett AA. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621-645. PMID: 9331545. PMID 9331545 | research article |
Related pair pages
More research context
Frequently asked
Have Ipamorelin and MK-677 been studied together?
Researchers have published mechanistic-level co-administration discussion of Ipamorelin and MK-677. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Ipamorelin and MK-677 share?
Ipamorelin and MK-677 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Ipamorelin and MK-677?
Ipamorelin: Not approved. MK-677: Not approved; WADA banned. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Ipamorelin and MK-677?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Ipamorelin profile and the MK-677 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026